Which closed-end funds own BioMarin Pharmaceutical Inc?
7 active closed-end funds report this security in their latest N-PORT filing, with a combined reported value of $6.4M. Security type: common equity. Country: United States. CUSIP 09061G101 · ISIN US09061G1013 · ticker BMRN.
Holdings are historical filings (report dates Jun 30, 2026; N-PORT becomes public ~60 days after quarter end), not live positions. Weights are percent of each fund’s net assets. Different instruments of one issuer (shares, bonds, preferreds) are separate securities — see related securities below.
Funds holding this security
| Fund | Category | Weight | Value (USD) | Balance | Fund net assets | Prem/disc | Report date |
|---|---|---|---|---|---|---|---|
| BME BlackRock Health Sciences Trust | Healthcare | 0.30% | $1.7M | 29,577 sh | $573M | 3.7% discount | Jun 30, 2026 |
| BMEZ BlackRock Health Sciences Term Trust | Healthcare | 0.17% | $1.8M | 31,662 sh | $1.1B | NAV unavailable | Jun 30, 2026 |
| JCE Nuveen Core Equity Alpha Fund | U.S. Equity | 0.07% | $204K | 3,560 sh | $302M | 5.9% discount | Jun 30, 2026 |
| TY Tri-Continental Corp | U.S. Equity | 0.05% | $1.1M | 19,534 sh | $2.1B | NAV unavailable | Jun 30, 2026 |
| ETW Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund | Covered Call / Option Income | 0.05% | $548K | 9,584 sh | $1.2B | 11.2% discount | Jun 30, 2026 |
| GAB Gabelli Equity Trust | U.S. Equity | 0.04% | $858K | 15,000 sh | $2.4B | 6.5% discount | Jun 30, 2026 |
| GDV Gabelli Dividend & Income Trust | U.S. Equity | 0.00% | $132K | 2,300 sh | $3.4B | 13.2% discount | Jun 30, 2026 |
7 positions. Source: SEC Form N-PORT via market-data vendor re-serve. Funds without an N-PORT on file cannot appear here.
Also listed in filings as: BIOMARIN PHARMACEUTICAL INC.
Related securities from the same issuer
| Security | Type | Funds holding |
|---|---|---|
| Biomarin Pharmaceutical | debt security | 17 |
| Biomarin Pharmaceutical Inc | loan | 11 |
Issuer-level search for “BMRN” → · Compare two funds’ portfolios →